Australia's most trusted
source of pharma news
Posted 21 May 2024 PM
Generics giant Arrotex has lost a battle in the Federal Court with the Minister for Health and Aged Care to have the April price reductions declared invalid, on the grounds it was in contravention of the Strategic Agreement signed with the Federal Government.
At the heart of the case was whether a price reduction which took effect for 84 pharmaceutical items on 1 October 2022 meant that the 1 April, 2024 price reductions should not have taken place because only 18 months had passed - not two years.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.